This Government Contract opportunity from Department Of Defense was posted on September 15, 2020. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Therapeutic Molecule Phenotypic Screening Capability services in support of USAMRIID

Awarded

W81XWH-20-C-0132Federal

Submission Closed09/14/2020, 12:00:00 AM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714

New

Federal

Pre-Clinical Models of Infectious Diseases

Solicitation # 75N93027R00003

National Institutes Of Health Niaid

POSTED

DEADLINE

Alternative Protein Technologies for Military Field Feeding

Solicitation # W911QY27ALTPROTEINS

POSTED

DEADLINE

USDA SBIR/STTR Topic 8.2 — Plant Production and Protection - Biology

Solicitation # USDA-NIFA-TOPIC-8.2

The USDA National Institute of Food and Agriculture is soliciting proposals under Topic 8.2 for Plant Production and Protection - Biology. This initiative focuses on advancing crop production and protection through the development of innovative plant breeding methods, diagnostic technologies for diseases, and the creation of new food and non-food crop plants. Research efforts are directed toward improving plant characteristics to mitigate biotic and abiotic stresses, developing new genotypes for commercial applications, and creating tools to support the health of natural and domesticated pollinators. This opportunity is a total small business set-aside under the SBIR/STTR mandate, restricting eligibility to companies with fewer than 500 employees. Managed by the United States Department of Agriculture, the program is led by Dr. Christopher Philips. Interested parties can find further details and application guidelines through the NIFA website.

National Institute of Food and Agriculture

POSTED

DEADLINE

Artificial Blood and Medical Consumable InnovationThe Artificial Blood and Medical Consumable Innovation subcontract supports the Defense Advanced Research Projects Agency within the Department of Defense. The scope of work involves providing innovative medical consumables and conducting biochemical research specifically focused on the development of artificial blood for prime contractors on DARPA Biological Technologies Office projects. The contractor is responsible for engineering scalable manufacturing processes for these consumables using sterile manufacturing facilities and bio-reactors. Key deliverables include the production of artificial blood prototypes and the implementation of scalable medical consumable solutions. This effort falls under NAICS code 541714, with a response deadline set for November 15, 2026.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Pre-Award Synopsis Texas Shield

Solicitation # DARPA-SN-27-07

The Defense Advanced Research Projects Agency (DARPA), through its Biological Technologies Office (BTO), intends to enter into an agreement with The University of Texas System consortium of universities for the Texas Shield Program. This integrated research initiative, identified by solicitation number DARPA-SN-27-07 and NAICS code 541714, focuses on developing autonomous and semi-autonomous medical technologies and scalable solutions for critical medical consumables. The primary goal is to support lifesaving medical care in contested, austere, and resource-limited environments. Key technical areas of focus include autonomous medical and robotic surgical systems, casualty evacuation, artificial-blood and supply innovation, AI-enabled clinical decision support, and mass-casualty science and simulation. This notice is a pre-award synopsis and is not a request for proposals or a competitive solicitation. Interested entities are invited to submit information by November 15, 2026, to TexasShieldxBTO@darpa.mil detailing their technical expertise, integrated research infrastructure, clinical-validation capabilities, and multi-institutional coordination capacity. Additionally, respondents must describe their consortium organizational structure, commercialization capabilities, facility clearance levels, and their ability to handle Controlled Unclassified Information. The government will not reimburse any costs associated with the preparation or submission of information in response to this notice.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Q--AMPLICON SEQUENCING SERVICES

Solicitation # 140G0226Q0047

Solicitation 140G0226Q0047 is a firm-fixed-price request for a Blanket Purchase Agreement (BPA) to provide next generation amplicon sequencing services for the USGS Upper Midwest Water Science Center’s Michigan Bacteriological Research Laboratory. The scope of work includes providing all equipment, labor, travel, and materials necessary to support research on bacterial pathogens, harmful algal blooms, microbial ecology, antibiotic resistance, and microbial source tracking. Key technical requirements include the use of Illumina MiSeq or AVITI sequencing technologies and the potential for library preparation for 16S V4 amplicon sequencing. The BPA has a total not-to-exceed value of 250,000 dollars with an estimated period of performance from September 17, 2026, to September 16, 2031. The award process prioritizes non-priced factors significantly over cost, focusing on the offeror's qualifications and technical performance. Evaluation criteria include a detailed listing of on-site equipment and calibration dates, personnel experience, internal quality assurance procedures, and a technical narrative not exceeding two pages. Performance will be executed in Lansing, Michigan, with delivery terms set as FOB Destination. Administrative requirements include electronic invoicing via the Internet Payment Platform and compliance with various federal regulations, including the Buy American Act and specific security prohibitions regarding telecommunications equipment. Proposals must be submitted to the USGS OAG Denver Acquisition Branch by September 11, 2026.

Ofc Of Acquisition Grants-Denver

POSTED

DEADLINE

RFI Lupus Research Program (LRP) Public

Solicitation # HT9427RFI2027LRP

The Defense Health Agency, through the Congressionally Directed Medical Research Programs, has issued a Request for Information regarding the Lupus Research Program for fiscal year 2027. This action is strictly for information and planning purposes to identify future research focus areas and funding opportunities; it is not a solicitation, and no contracts will be awarded based on this announcement. The program aims to cure lupus by funding research to improve diagnosis, prevention, and treatment, with a specific focus on understanding biological or genetic patient subsets, disease mechanisms, and enhancing overall patient quality of life. Interested parties from academia, industry, non-profit organizations, and the public are invited to provide feedback on critical research gaps and underfunded areas. Responses must be submitted via Survey Monkey by November 16, 2026. While historical appropriations from fiscal years 2017 through 2024 and 2026 totaled 75 million dollars, funds for fiscal year 2027 have not yet been appropriated. Respondents are cautioned not to submit proprietary or sensitive information through the survey portal, as the government cannot protect such data, and all costs associated with responding to this request are the responsibility of the participant.

Defense Health Agency

POSTED

DEADLINE

Clinical Trial Site Operations and Participant ManagementThis subcontract for Clinical Trial Site Operations and Participant Management supports prime contractors on NIH/NIDDK projects through the direct execution of clinical trials. The scope of work includes recruiting and enrolling study participants, implementing lifestyle intervention weight loss programs, and conducting scheduled study visits and clinical procedures. To ensure compliance and quality, the provider must maintain IRB approval, active SAM/eRA Commons registration, and utilize specialized clinical trial facilities equipped with medical-grade ultra-low temperature freezers for biospecimen storage. The primary deliverables for this engagement consist of completed participant visits, curated patient data, and the collection of biospecimens. This opportunity is associated with NAICS code 541714 and falls under the jurisdiction of the National Institutes of Health within the Department of Health and Human Services. The response deadline for this requirement is November 17, 2026.

National Institutes Of Health

POSTED

DEADLINE

replacement skidsteerutility vehicle and attachmentsThe US Geological Survey, under the Department of the Interior, is forecasting the acquisition of a replacement skidsteer utility vehicle and associated attachments. This procurement is intended to support the National Wildlife Health Center located in Madison, Wisconsin, specifically benefiting the Midcontinent Region and Ecosystems Mission Area. The project is categorized under NAICS code 541714 and is listed as a forecast with a posted date of October 14, 2026. Sean Jones serves as the primary point of contact and small business specialist for this requirement.

POSTED

DEADLINE

Preclinical & Translational Research SupportThis subcontract for Preclinical and Translational Research Support involves providing specialized laboratory services and preclinical testing to prime contractors working on Defense Health Agency lupus research projects. The scope of work focuses on supporting the transition from laboratory research to clinical application through the development of animal models, in-vitro and in-vivo modeling, and preclinical toxicity testing. The primary deliverables include validated models and comprehensive preclinical test results. The project is managed under the Department of Defense for the Defense Health Agency and is categorized under NAICS code 541714. Performance of the contract will take place in Frederick, Maryland. Interested parties should note the response deadline of November 16, 2026.

Defense Health Agency

POSTED

DEADLINE

Patient Quality of Life (QoL) Clinical StudiesThis subcontract focuses on conducting patient-centric clinical research for the Defense Health Agency to evaluate factors affecting the quality of life for lupus patients. The scope of work includes comprehensive clinical trial management, the design of patient surveys, psychosocial assessments, and detailed health outcomes research. The primary objective is to generate and deliver clinical study reports and outcome data to prime contractors. The project is categorized under NAICS code 541714 and will be performed in Frederick, Maryland. Interested parties should note that the response deadline is November 16, 2026, following a posting date of October 14, 2026.

Defense Health Agency

POSTED

DEADLINE

Disease Mechanism & Intervention ResearchThis subcontract opportunity involves conducting specialized research into lupus disease mechanisms and analyzing patient responses to medical interventions to support prime contractors on Defense Health Agency projects. The scope of work focuses on translational research, pharmacological studies, and the mapping of disease pathways to deliver critical analysis of intervention response data. The project is associated with NAICS code 541714 and will be performed in Frederick, Maryland. Interested parties should note that the solicitation was posted on October 14, 2026, with a response deadline set for November 16, 2026.

Defense Health Agency

POSTED

6 days ago

DEADLINE

in 27 days

AI Contract Overview

The Department of Defense awarded a firm-fixed price, sole source contract to The Geneva Foundation for Therapeutic Molecule Phenotypic Screening Capability services in support of USAMRIID. This award, identified by solicitation number W81XWH-20-C-0132, was granted under FAR 6.302-1 because The Geneva Foundation is the only vendor possessing the specialized skills and knowledge required for phenotypic drug screening against BSL-3 viral pathogens. Their unique expertise includes the use of the Opera high content imaging system, associated liquid handling instruments, and specific data analysis workflows. The contract is further justified by the foundation's active participants in USAMRIID's BPRP, which allows for immediate access to necessary containment suites. Given the critical need to maintain high content screening capabilities at USAMRIID, The Geneva Foundation was determined to be the only source capable of meeting the government's requirements. The work is performed in Frederick, Maryland, under the oversight of the USA Medical Research Acquisition Activity.

General Info

Agency

Department Of Defense → W4PZ USA Medical Rsch Acquis Act

Contract Value

$451,462.9

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Frederick, MD, 21702, USA

Set-Aside

NONE

Awardee

THE GENEVA FOUNDATION

Award Issued Date

09/28/2020, 12:00:00 AM UTC

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

1 update

PhaseAwarded

PostedSep 15

Award Notice

Justification (J&A)Sep 15

Justification & Approval published

AwardedSep 28

Contract was awarded

Submission Closed

09/14/2020, 12:00:00 AM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Defense → W4PZ USA Medical Rsch Acquis Act

Contacts2 people available

OfficeFORT DETRICK, MD, 21702-5014, USA

Organization / AgencyDepartment Of Defense → W4PZ USA Medical Rsch Acquis Act

Office AddressFORT DETRICK, MD, 21702-5014, USA

Contacts

Erik Przygocki

contact@example.gov

Jayme L. Fletcher

contact@example.gov

Full Description

A firm-fixed price, sole source contract was awarded to The Geneva Foundation under the authority as prescribed in FAR 6.302-1 -- Only one responsible source. The Geneva Foundation is the only vendor with demonstrated skills, knowledge, and abilities associated with phenotypic drug screening against BSL-3 viral pathogens using the Opera high content imaging system, affiliated liquid handling instruments, and data analysis programs and workflow. Additionally, The Geneva Foundation is the only vendor with active participants in USAMRIID's BPRP enabling immediate access to the containment suites. Further, due to the critical need to continue the high content screening capability at USAMRIID, The Geneva Foundation is the only vendor capable of providing the services needed to meet the government's need.

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Join 750+ contractors already using CLEATUS